Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma

ABSTRACT Background Approximately 30% of patients with diffuse large B‐cell lymphoma (DLBCL) relapse or are refractory to first‐line treatment. This study aimed to determine the effectiveness and tolerability of the combination of Polatuzumab vedotin and Zanubrutinib plus Rituximab (Pola‐ZR) or Obin...

Full description

Saved in:
Bibliographic Details
Main Authors: Yian Zhang, Yuhong Ren, Jingli Zhuang, Ling Yuan, Zhimei Wang, Xuejiao Zhang, Weiguang Wang, Zhixiang Cheng, Luya Cheng, Jing Li, Peng Liu
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Cancer Medicine
Subjects:
diffuse large B‐cell lymphoma
effectiveness
Polatuzumab vedotin
relapsed/refractory
safety
Online Access:https://doi.org/10.1002/cam4.71162
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.71162

Similar Items